Loading...

AI Automation Platform Will Benefit From Long Term Cross System Workflow Complexity

Published
12 Mar 26
Views
0
n/a
n/a
AnalystHighTarget's Fair Value
n/a
Loading
1Y
14.0%
7D
-1.6%

Author's Valuation

US$1733.1% undervalued intrinsic discount

AnalystHighTarget Fair Value

Catalysts

About UiPath

UiPath provides an end to end automation and AI platform that helps enterprises automate complex workflows across systems, people and software.

What are the underlying business or industry changes driving this perspective?

  • The shift toward AI driven operating models is encouraging large customers to adopt UiPath’s agentic and AI products on top of existing unattended automation. This can widen platform usage and support ARR growth and higher net retention over time.
  • Enterprises are increasing cloud deployment of automation, and UiPath reported over US$1.2b in cloud ARR. This positions the company to capture more recurring revenue as customers standardize automation and orchestration in the cloud.
  • Growing complexity of cross system workflows is pushing companies to look for a unified control layer. UiPath’s Maestro and coding agents are designed to shorten automation build times, which can support faster revenue realization and potentially improve operating margins through efficiency gains.
  • Rising compliance and governance requirements in sectors such as financial services and the public sector are steering buyers toward platforms with strong auditability and security. UiPath’s focus on governance can help support premium pricing and resilient net margins.
  • Health care and financial services are seeing increased interest in revenue cycle, financial crime and other high stakes use cases where UiPath is building dedicated solutions and integrating WorkFusion. This can support higher expansion rates, larger deal sizes and earnings growth as these offerings scale.
NYSE:PATH Earnings & Revenue Growth as at Mar 2026
NYSE:PATH Earnings & Revenue Growth as at Mar 2026

Assumptions

This narrative explores a more optimistic perspective on UiPath compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

  • The bullish analysts are assuming UiPath's revenue will grow by 9.4% annually over the next 3 years.
  • The bullish analysts assume that profit margins will shrink from 17.5% today to 9.7% in 3 years time.
  • The bullish analysts expect earnings to reach $204.2 million (and earnings per share of $0.62) by about March 2029, down from $282.3 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $22.9 million.
  • In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 52.3x on those 2029 earnings, up from 21.5x today. This future PE is greater than the current PE for the US Software industry at 28.1x.
  • The bullish analysts expect the number of shares outstanding to decline by 2.82% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 8.51%, as per the Simply Wall St company report.
NYSE:PATH Future EPS Growth as at Mar 2026
NYSE:PATH Future EPS Growth as at Mar 2026

Risks

What could happen that would invalidate this narrative?

  • AI and automation demand may increasingly favor usage based or pure SaaS models. UiPath still accounts for a meaningful mix of hybrid and non SaaS ARR, which could slow new ARR if large customers prefer alternatives and weigh on revenue growth.
  • Growing competition in agentic AI and orchestration from system of record vendors and AI native providers, some of which customers already use for core workflows, could limit adoption of Maestro and UiPath agents and put pressure on pricing, which would affect ARR expansion and net margins.
  • If AI products and vertical solutions such as healthcare revenue cycle or financial crime agents fail to scale as expected or take longer to integrate with WorkFusion than planned, the mix shift toward higher value AI ARR may stall and reduce the contribution to earnings growth and operating margin expansion.
  • The company is leaning heavily on partners and large, complex projects in regulated sectors like public sector, financial services and healthcare. Any slowdown in these long sales cycle markets or delays in long term projects could dampen large deal volume and weigh on revenue and earnings.
  • Management is targeting higher long term non GAAP operating margins and expects continued GAAP profitability. However, heavier cloud investment, stock based compensation, internal use of agents and potential tuck in acquisitions could keep costs elevated and limit further improvement in net margins and free cash flow.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The assumed bullish price target for UiPath is $17.0, which represents up to two standard deviations above the consensus price target of $13.99. This valuation is based on what can be assumed as the expectations of UiPath's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $17.0, and the most bearish reporting a price target of just $12.0.
  • In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $2.1 billion, earnings will come to $204.2 million, and it would be trading on a PE ratio of 52.3x, assuming you use a discount rate of 8.5%.
  • Given the current share price of $11.37, the analyst price target of $17.0 is 33.1% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on UiPath?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

US$21.54
FV
47.2% undervalued intrinsic discount
10.00%
Revenue growth p.a.
498
users have viewed this narrative
1users have liked this narrative
0users have commented on this narrative
21users have followed this narrative
US$15.93
FV
28.6% undervalued intrinsic discount
8.96%
Revenue growth p.a.
2k
users have viewed this narrative
4users have liked this narrative
0users have commented on this narrative
168users have followed this narrative